New diabetes clinical trial: Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
Published on: 2026-03-12T04:00:00Z
Conditions: Cardiovascular-kidney-metabolic Syndrome; Cardiovascular Disease Risk Factor; Kidney Disease; Type 2 Diabetes; Obesity & Overweight
Interventions: Drug: GLP-1 receptor agonist; Drug: SGLT2 inhibitor
Sponsors: Chung Shan Medical University; National Science and Technology Council, Taiwan
Completed
https://ift.tt/VNm4XBO
Conditions: Cardiovascular-kidney-metabolic Syndrome; Cardiovascular Disease Risk Factor; Kidney Disease; Type 2 Diabetes; Obesity & Overweight
Interventions: Drug: GLP-1 receptor agonist; Drug: SGLT2 inhibitor
Sponsors: Chung Shan Medical University; National Science and Technology Council, Taiwan
Completed
https://ift.tt/VNm4XBO
Comments
Post a Comment